Colorectal Cancer, Lung Metastasis
Conditions
Keywords
Colorectal cancer, lung metastasis, radiofrequency ablation, metastasectomy, Lung metastasis from colorectal cancer
Brief summary
Lung metastasectomy is the only therapeutic option to provide a long-survival in patients with colorectal lung metastases. Recent studies have shown that radiofrequency (RF) ablation is a safe and useful therapeutic option for the treatment of unresectable lung metastases. In this phase-II trial, clinical utility of lung RF ablation will be evaluated in patients with resectable colorectal lung metastases.
Detailed description
This will be a phase-II clinical trial. Lung metastasectomy is the only therapeutic option to provide a long-survival in patients with colorectal lung metastases. Recent studies have shown that radiofrequency (RF) ablation is a safe and useful therapeutic option for the treatment of unresectable lung metastases. In this clinical trial, clinical utility of lung RF ablation will be evaluated. Patients with resectable lung metastases will receive lung RF ablation. All subjects will be followed for overall survival, safety, change in respiratory function, cancer-specific survival, and local tumor progression.
Interventions
A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
Sponsors
Mie University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary lesions (colorectal cancer) are resected. * Lung metastases appear. * No extrapulmonary metastases or after locoregional treatments. * Lung metastasis is considered to be controllable either by metastasectomy or radiofrequency (RF) ablation. * Five or less lung metastases measuring 3cm or smaller. * PET study within 8 weeks before metastasectomy or RF ablation. * White blood count of 3000/mm3 or more. * Platelet count of 100,000/mm3 or more. * Hemoglobin level of 8.0 g/dl. * Serum creatinine level of 2.0 mg/dl or less. * PaO2 of 70 mm Hg or more（Room air）or SpO2 of 93%. * Serum bilirubin level of 2.0 mg/dl or less. * Performance status of 0 or 1. * Expected survival of 1 year or more. * Age of 20 years or more. * Informed consent from the patient.
Exclusion criteria
* Risk to injure lung vessels 5 mm or larger. * Lung metastases adjacent to the heart, trachea, esophagus, and aorta. * Association of uncontrollable malignancies. * Lung hilar lymph node metastasis. * One lung. * Pulmonary hypertension. * Coagulopathy. * Impossible to stop using anticoagulants. * Active infection or C-reactive protein of 3 or higher. * Association of active inflammation. * Fever (higher than 38 degrees celsius). * Previous external-beam radiotherapy for the treated lung. * Pregnant. * Judgment to be an inappropriate candidate by a attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measures:3-year survival | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies | 3 years |
Countries
Japan
Outcome results
None listed